<DOC>
	<DOCNO>NCT00368849</DOCNO>
	<brief_summary>The purpose research study evaluate effect atomoxetine ( also know Strattera ) compare placebo ( inactive substance ) daily activity attention focus , think ability muscle movement subject early Huntington Disease ( HD ) attention deficit disorder ( ADD ) .</brief_summary>
	<brief_title>Atomoxetine Huntington 's Disease</brief_title>
	<detailed_description>No medication investigate improve attention executive function patient Huntington 's disease , despite evidence cognitive domain abnormal even motor symptom onset . Because cognitive symptom highly associate functional disability , treatment aim improve cognitive function would significant benefit patient early stage disease . Atomoxetine ideal choice trial . It proven efficacy adult attention deficit hyperactivity disorder ( ADHD ) selectively target norepinephrine dopamine prefrontal cortex rather subcortical area . This selectivity advantage patient HD , motor side effect less likely facilitate psychostimulant . The present study feasibility study propose administer either 80 milligram ( mg ) atomoxetine 4 week placebo 20 patient early HD also complain mild cognitive symptom . The group crossover condition ( atomoxetine placebo ) . Participants assess measure ADHD symptom sensitive battery neuropsychological test . Based shared neural circuitry ADHD HD , demonstrate effectiveness atomoxetine attention adult ADHD , improve performance cognitive test attention executive function subject ' report ADHD symptom expect atomoxetine treatment phase . No change motor status predict study .</detailed_description>
	<mesh_term>Huntington Disease</mesh_term>
	<mesh_term>Chorea</mesh_term>
	<mesh_term>Atomoxetine Hydrochloride</mesh_term>
	<criteria>Confirmed Huntington 's disease ( HD ) diagnosis Age 18 65 Must mild HD Must complaint poor attention Childhood history attention deficit hyperactivity disorder ( ADHD ) symptoms Diagnosis schizophrenia , bipolar affective disorder , dementia , delirium severe anxiety Current use monoamine oxidase inhibitor ( MAOI ) medication Pregnancy Uncontrolled hypertension Tachycardia Cardiovascular cerebrovascular disease History loss consciousness great ( equal ) 5 minute Having neurological disorder insult Huntington disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Huntington Disease</keyword>
	<keyword>Chorea</keyword>
	<keyword>Attention</keyword>
	<keyword>ADHD</keyword>
	<keyword>ADD</keyword>
	<keyword>Strattera</keyword>
	<keyword>Atomoxetine</keyword>
</DOC>